Markets

Ocular Therapeutix (OCUL) in Focus: Stock Goes Down 6.4% - Tale of the Tape

Ocular Therapeutix, Inc. ( OCUL ) saw a big move in the last trading session, as the company's shares fell by over 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent trend for OCUL, as the stock is now down over 29% in the past one-month time frame.

On Apr 6, the company announced disappointing results from its second phase III study on its pipeline candidate OTX-DP, which failed to meet one of the two primary efficacy endpoints.

This slump shouldn't be too much of a surprise to investors, as the biopharmaceutical company has seen 1 negative revision in the past few weeks and its current year earnings consensus has also moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.

OCUL currently holds a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Drugs industry may consider a better-ranked stock like Flamel Technologies SA ( FLML ), carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OCULAR THERAPTX (OCUL): Get Free Report

FLAMEL TECH (FLML): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

OCUL

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More